News
The day at a glance · 2 min read
Mood · Risk-On
+62
Sentiment, −100 to +100
DXCM 30-day return
17.09%+17.09%
DXCM 90-day return
34.06%+34.06%
DXCM closing price
$89.75
Key driverMedical device makers and Big Pharma partnerships drive positive momentum across healthcare equities
Daily briefHealthcare· Money365.Market AI ·

MedTech Gains Momentum, Lilly Expands Partnerships

DexCom rebounds strongly while Eli Lilly secures OmniAb licensing deal; AbbVie target raised to $300

MedTech & Devices

Bullish
DXCM
DexCom ($DXCM) attracted investor attention following recent share price momentum, with the continuous glucose monitoring company closing at $89.75. The stock posted gains of 17.09% over the past 30 days and 34.06% over the past 90 days, contrasting with more modest longer-term performance.
Stryker Corporation also drew analyst attention with reports highlighting the medical device manufacturer's 11% organic revenue growth and expanding margins, though analysts recommended waiting for a price correction before entry.

Big Pharma & Biotech

Bullish

OmniAb-Lilly deal milestones

$370 million

ABBV price target (Wells Fargo)

$300+$5
LLYABBV
Eli Lilly ($LLY) secured a licensing agreement with OmniAb valued at up to $370 million in milestone payments, prompting shares of the antibody discovery platform provider to rally in premarket trading. The deal contributed to $LLY raising its 2026 cash outlook. Separately, Eli Lilly Canada stated it continues to take action addressing the promotion and sale of unapproved and illegal retatrutide products in Canada, disagreeing with characterizations in a Canada Revenue Agency application and planning to respond formally through the court process.
AbbVie ($ABBV) received a price target increase from Wells Fargo analyst Mohit Bansal, who raised his target from $295 to $300 while maintaining an Overweight rating on the stock.

Analyst Activity & Large Trades

Neutral

ABT sale range (low)

$25,025

ABT sale range (high)

$375,000
PFEABTJNJ
Institutional activity picked up across healthcare names, with whale alerts identifying large options transactions in Pfizer ($PFE) and other healthcare stocks. Representative Richard Dean Dr McCormick of Georgia disclosed a sale of Abbott Laboratories ($ABT) stock valued between $25,025 and $375,000, with the transaction dated July 30, 2026, according to records from August 14, 2026.
Johnson & Johnson ($JNJ) received recognition for passing dividend quality screens with a high dividend rating, robust profitability, and solid financial health, positioning it as a reliable income investment.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy